OliX Pharmaceuticals, Inc. Q3 operating loss of KRW 16.3 billion, larger than a year earlier
AI summary · Not investment advice
Olix sold KRW 2.2 billion in Q3 and lost KRW 16.3 billion from its main business, versus sales of KRW 2.9 billion and a KRW 8.3 billion loss a year earlier.
Operating profit · 3 months
KRW -16.3 billion
Key facts
- Revenue (3 months)
- KRW 2.2 billion
- Net income (3 months)
- KRW -12.2 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 2.9 billion
- Revenue (year to date)
- KRW 8.4 billion
- Operating profit (prior-year 3 months)
- KRW -8.3 billion
- Operating profit (year to date)
- KRW -41.1 billion
- Net income (prior-year 3 months)
- KRW -8.7 billion
- Net income (year to date)
- KRW -32.9 billion
Commentary
AI commentary · Not investment advice
What happened
Olix reported its consolidated results for the third quarter of 2026 in its quarterly report. Sales for the latest 3 months were KRW 2.16 billion, down 25.7% from the same period a year earlier. Cumulative sales this year are KRW 8.36 billion.
In the company's terms
Operating profit (profit from the core business) for the latest 3 months was a loss of KRW 16.31 billion. A year earlier, the 3-month figure was a loss of KRW 8.31 billion. The cumulative operating loss this year is KRW 41.10 billion.
What changes for shareholders
Net income (final profit after taxes and all other items) for the latest 3 months was a loss of KRW 12.15 billion. A year earlier, the 3-month figure was a loss of KRW 8.66 billion. The cumulative net loss this year is KRW 32.91 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
O